Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG Piramal Pharma Ltd - 543635 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March, 2024. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Please refer attachment. Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (listing Obligations and DIsclsoure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection of Piramal Pharma''s manufacturing facility located at Lexington, USA. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2024
Piramal Pharma Q4 Results Review - Solid Quarter; Grim Near-Term Outlook: ICICI Securities
Contract development manufacturing organisation outlook intact, investment in complex hospital generics business on rise
In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
Nandini Piramal projects early teens revenue growth for FY25 and 22-25% EBITDA growth margins in 3-5 years. Revenue increase drives margin expansion through cost optimization and operational excellence, with a focus on CDMO and Indian consumer products growth. On-patent and differentiated offerings will give Piramal Pharma an edge, says Chairperson
The strategy is to stay the course and grow CDM and consumer healthcare businesses Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2024